The NR1H3 antibody is a crucial tool for studying the nuclear receptor subfamily 1 group H member 3 (NR1H3), also known as liver X receptor alpha (LXRα). NR1H3 is a ligand-activated transcription factor that regulates genes involved in cholesterol metabolism, lipid homeostasis, and inflammation. It forms heterodimers with retinoid X receptor (RXR) and binds to LXR response elements in target gene promoters, influencing pathways like reverse cholesterol transport, fatty acid synthesis, and glucose metabolism. Dysregulation of NR1H3 is linked to metabolic disorders, atherosclerosis, and cancer.
NR1H3 antibodies are widely used in research to detect and quantify LXRα expression in tissues or cells via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate NR1H3's role in disease mechanisms, drug responses, and transcriptional regulation. Some antibodies target specific domains, such as the DNA-binding domain (DBD) or ligand-binding domain (LBD), enabling studies on receptor activation or interaction with co-regulators.
These antibodies are vital for exploring NR1H3's potential as a therapeutic target, particularly in metabolic syndrome and inflammatory conditions. Validation steps, including knockout controls and peptide blocking, ensure specificity. By enabling precise detection of NR1H3. these reagents advance our understanding of its physiological and pathological functions, supporting drug discovery and biomarker development.